Loading clinical trials...
Loading clinical trials...
A Cohort Study to Evaluate the Impact of Inactivated Trivalent Influenza Vaccine on the Immunogenicity, Safety and Survival of Non-small Cell Lung Cancer Patients Receiving PD-1 / PD-L1 Inhibitors
Conditions
Interventions
PD-1/PD-L1 inhibitors
Inactivated trivalent influenza vaccine
Locations
2
China
School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong
Hong Kong, Hong Kong, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Start Date
June 1, 2020
Primary Completion Date
December 31, 2022
Completion Date
May 31, 2023
Last Updated
April 21, 2020
NCT06066138
NCT07485114
NCT05098132
NCT06284317
NCT06731413
NCT06687369
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions